Viewpoint Molecular Targeting® is a precision oncology company developing alpha-particle therapies and coordinated diagnostic imaging agents. Viewpoint’s Pb-212-based alpha-particle radiotherapies utilize specialized targeting peptides to deliver powerful alpha radiation specifically cancer cells. Viewpoint is also developing complementary imaging diagnostics that employ elementally identical Pb-203-labeled radiopeptides for the purpose of personalizing treatment and optimizing patient outcomes. This theranostic approach is designed to leverage quantitative imaging information to improve efficacy and minimize potential toxicities associated with many other types of cancer treatments.
The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT-𝛼-NET) programs are enrolling in Phase 1 imaging studies that will be followed by Phase 1/2a therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at leading academic institutions and theranostic practices.